Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung
This clinical trial investigates the acceptability of electronic cigarettes (JUUL) for smoking cessation (quitting smoking) and the reduction of surgery-related complications in patients with newly diagnosed head, neck, or lung cancer. Smoking before surgery is associated with increased risk of complications during and after surgery. Electronic cigarettes are a type of special product that gives small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking. Stopping cigarette smoking before surgery may reduce the risk of complications during and after surgery in patients with head, neck, or lung cancer.
Checked against the public recordLast updated Apr 12, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Interventions being studied
- Other: Best Practice; Drug: Nicotine Replacement; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Newly diagnosed lung cancer subjects will be stages I-III non-small cell lung cancer (NSCLC) and head and neck cancer subjects will be stages I-IV squamous cell carcinoma (SCC). * Current smokers of combustible cigarettes who smoke \>= 4 days/week. * Lung cancer patients planning to undergo wedge resection surgery for their index cancer. * Head and neck cancer patients planning to undergo surgical resection of their index cancer or exploratory biopsies (tonsil cancer). * Patients must intend to receive ongoing oncology care at Ohio State University \[OSU\] (i.e., their clinic visit is not a consultation/second opinion). * Patients that are over the age of 21 years. Exclusion Criteria: * Patients who are cognitively unable to understand the consent form or participate in interviews. * Patients with hearing impairments. * Patients who are planning to use or are currently using cessation medication to help quit or reduce smoking. * Patients who are currently using e-cigarettes. * Patients undergoing surgery including lobectomy, pneumonectomy, tracheotomy, laryngectomy, or free flap surgery. * Patients with contraindications to per oral intake. * Lung cancer patients who are on home supplemental oxygen at baseline. * Patients that have problems with dexterity that would impact electronic cigarette use. * Patients under 21 years of age. * Patients who don't speak and read English. * Patients with histologies other than NSCLC, or squamous cell carcinoma of the head and neck. * Patients with nasopharyngeal, thyroid, or gland cancers. * Patients with inoperable tumors. * Pregnant women. * Prisoners.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 12, 2024. Always confirm current availability with the study team.